期刊
MOLECULAR PHARMACEUTICS
卷 15, 期 2, 页码 585-591出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.7b00952
关键词
squalenoylated drugs; molecular dynamics; docking; low-density lipoproteins; human serum albumin
资金
- GENCI-[TGCC/CINES/IDRIS] [2015-[c2016077586], 2016-A0020707586]
- European Union's Horizon research and innovation program under the Marie Sklodowska-Curie grant [690853]
- NATO Science for Peace and Security program [SPS 985291]
- Marie Curie Actions (MSCA) [690853] Funding Source: Marie Curie Actions (MSCA)
We have studied the interaction of three clinically promising squalenoylated drugs (gemcitabine-squalene, adenine-squalene, and doxorubicin-squalene) with low-density lipoproteins (LDL) by means of atomistic molecular dynamics simulations. It is shown that all studied squalenoylated drugs accumulate inside the LDL particles. This effect is promoted by the squalene moiety, which acts as an anchor and drives the hydrophilic drugs into the hydrophobic core of the LDL lipid droplet. Our data suggest that LDL particles could be a universal carriers of squalenoylated drugs in the bloodstream. Interaction of gemcitabine-squalene with human serum albumin (HSA) was also studied by ensemble of docking simulations. It is shown that HSA could also act as a passive carrier of this bioconjugate. It should be noted that the binding of squalene moiety to HSA was unspecific and did not occur in the binding pockets devoted to fatty acids.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据